THX-TS01

Drug Profile

THX-TS01

Alternative Names: THX RS01; THX TS01

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Therapix Biosciences
  • Class Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gilles de la Tourette's syndrome

Most Recent Events

  • 23 Dec 2016 Phase-II clinical trials in Gilles de la Tourette's syndrome in USA (unspecified route)
  • 01 Jul 2016 Therapix Biosciences and Yale University files an iIND application with the FDA in USA for Tourette's syndrome (Therapix Biosciences Quarterly Report, August 2016)
  • 15 Jun 2016 Therapix Biosciences applies for Orphan drug designation for Gilles de la Tourette's syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top